Clinical Trials Logo

Clinical Trial Summary

The study proposes the characterization of the intestinal and vaginal microbiota in long-term radiated cervical and endometrial cancer survivors to study the association with long-term radiotherapy side effects.


Clinical Trial Description

The human epithelial surface is colonized by a community of microorganisms, the microbiota, which disruption (dysbiosis) can impact a variety of functions, leading to inflammation, altered immunity and numerous diseases, including cancer. Pelvic cancers are among the most frequently diagnosed cancers worldwide, and pelvic radiotherapy is often an essential part of multimodal therapeutic approaches but can lead to a wide range of complications for which there is currently no treatment. The gut microbiota is altered by radiotherapy, and a relationship between gut microbiota composition, health status, and pelvic radiotherapy has been suggested. In recent years, there has been growing evidence that radiotherapy also alters the vaginal microbiota. The study proposes the characterization of the intestinal and vaginal microbiota in long-term radiated cervical and endometrial cancer survivors to study its association with long-term radiotherapy side effects. For this purpose, a descriptive cross-sectional study will be carried out in patients affected by cervical or endometrial cancer, in early stages, with good vital prognosis who have received radiotherapy, using healthy postmenopausal women as a control group. If the microbiota is indeed associated with the side effects of radiotherapy, this would open the possibility of identifying predictive markers, using machine learning analysis of the patients' quality of life, and would help in the search for future therapies based on the restoration of the vaginal and intestinal microbiota. Through network analysis, it would be possible to find out which factors related to patients' diet and lifestyle could be related to dysbiosis and radiotherapy-induced adverse outcomes and poor quality of life. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05360459
Study type Observational
Source Universidad Autonoma de Madrid
Contact María Bailen Andrino, PhD
Phone 0034629606088
Email mariabailen@gmail.com
Status Recruiting
Phase
Start date May 20, 2022
Completion date May 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05051696 - Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies Phase 2
Completed NCT00377520 - A Trial for Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT04566952 - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Phase 2
Completed NCT02182245 - Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies Phase 1
Completed NCT00191646 - An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Phase 3
Completed NCT00121030 - Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy Phase 2
Recruiting NCT04556071 - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Phase 2
Completed NCT04679675 - Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial N/A
Terminated NCT00332280 - Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo Phase 2/Phase 3
Not yet recruiting NCT04807166 - Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Phase 2
Completed NCT02966327 - Effect of Early Compression and Exercise on Lymphedema Incidence in Patients With Gynecological Cancer N/A
Completed NCT01654458 - A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer N/A
Completed NCT02609880 - Cognitive Behavioral Effects on Sleep, Pain, and Cytokines in Gynecologic Cancer N/A
Completed NCT00191607 - A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. Phase 3
Terminated NCT02499952 - Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors Phase 2
Terminated NCT01032447 - Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program N/A
Recruiting NCT02781155 - Limiting Chemotherapy Side Effects by Using Moxa Phase 1/Phase 2
Recruiting NCT00391664 - Questionnaire Study for Gynecological Cancer Survivors N/A
Completed NCT00190983 - A Trial for Patients With Advanced/Recurrent Cervical Cancer Phase 2
Completed NCT00523432 - A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies Phase 1